Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood,
urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor …

Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood.
ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Abstract Background Circulating tumour DNA (ctDNA) has emerged as an excellent
candidate for the future of liquid biopsies for many cancers. There has been growing interest …

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high
specificity and sensitivity in patients with colorectal cancer. A “liquid biopsy” is characterized …

During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …